Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Jan 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telmisartan (Primary)
Indications Peripheral arterial disorders
Focus Therapeutic Use
Acronyms TELEX

Most Recent Events

04 Oct 2022 Primary endpoint has not been met (Six-minute walk performance) , according to Results published in the JAMA: the Journal of the American Medical Association
04 Oct 2022 Results published in the JAMA: the Journal of the American Medical Association
29 Aug 2022 Status changed from recruiting to completed.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight